<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cyclerion Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc</link>
<description>Latest news and press releases for Cyclerion Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cyclerion-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355b7678dffbe2df0ebe85.webp</url>
<title>Cyclerion Therapeutics, Inc.</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc</link>
</image>
<item>
<title>Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-and-korsana-biosciences-announce-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-and-korsana-biosciences-announce-merger-agreement</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases</description>
</item>
<item>
<title>Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-progress-toward-120000776</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-progress-toward-120000776</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) (“Cyclerion</description>
</item>
<item>
<title>Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-strategic-agreement-210100332</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-strategic-agreement-210100332</guid>
<pubDate>Mon, 05 Jan 2026 21:01:00 GMT</pubDate>
<description>– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company pioneering neur</description>
</item>
<item>
<title>Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-transformational-relaunch-neuropsychiatric-200100838</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-transformational-relaunch-neuropsychiatric-200100838</guid>
<pubDate>Tue, 23 Sep 2025 20:01:00 GMT</pubDate>
<description>– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology (“MIT”), securing the intellectual property that will serve as the cornerstone of its strategic relaunc</description>
</item>
<item>
<title>Regina Graul, Ph.D., Promoted to Chief Executive Officer</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/regina-graul-phd-promoted-to-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/regina-graul-phd-promoted-to-chief-executive-officer</guid>
<pubDate>Wed, 07 Aug 2024 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted</description>
</item>
<item>
<title>Cyclerion Appoints Regina Graul, Ph.D., as President</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-appoints-regina-graul-phd-as-president</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-appoints-regina-graul-phd-as-president</guid>
<pubDate>Mon, 04 Dec 2023 05:00:00 GMT</pubDate>
<description>– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in</description>
</item>
<item>
<title>Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-strengthens-board-of-directors-with-experienced-company-builder-and-cutting-edge-innovator</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-strengthens-board-of-directors-with-experienced-company-builder-and-cutting-edge-innovator</guid>
<pubDate>Thu, 30 Nov 2023 05:00:00 GMT</pubDate>
<description>- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms,</description>
</item>
<item>
<title>Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Thu, 01 Jun 2023 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has</description>
</item>
<item>
<title>Cyclerion Announces Reverse Stock Split</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-reverse-stock-split</guid>
<pubDate>Mon, 15 May 2023 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN)</description>
</item>
<item>
<title>Cyclerion Announces Corporate Updates and Q1 2023 Financial Results</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-corporate-updates-and-q1-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-corporate-updates-and-q1-2023-financial-results</guid>
<pubDate>Thu, 11 May 2023 04:00:00 GMT</pubDate>
<description>Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and</description>
</item>
<item>
<title>Cyclerion Announces Definitive Agreement for Zagociguat and CY3018</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-definitive-agreement-for-zagociguat-and-cy3018</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-definitive-agreement-for-zagociguat-and-cy3018</guid>
<pubDate>Thu, 11 May 2023 04:00:00 GMT</pubDate>
<description>Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion</description>
</item>
<item>
<title>Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-enters-into-exclusive-negotiation-period-and-binding-equity-investment-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-enters-into-exclusive-negotiation-period-and-binding-equity-investment-agreement</guid>
<pubDate>Mon, 03 Apr 2023 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company,</description>
</item>
<item>
<title>Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-receives-us-fda-orphan-drug-designation-for-zagociguat-for-the-treatment-of-mitochondrial-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-receives-us-fda-orphan-drug-designation-for-zagociguat-for-the-treatment-of-mitochondrial-diseases</guid>
<pubDate>Mon, 27 Mar 2023 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to</description>
</item>
<item>
<title>Cyclerion Reports Corporate Update and Full Year 2022 Financial Results</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-reports-corporate-update-and-full-year-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-reports-corporate-update-and-full-year-2022-financial-results</guid>
<pubDate>Wed, 22 Mar 2023 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its</description>
</item>
<item>
<title>Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-concludes-unsolicited-proposal-is-not-in-the-best-interest-of-the-company</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-concludes-unsolicited-proposal-is-not-in-the-best-interest-of-the-company</guid>
<pubDate>Tue, 22 Nov 2022 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company</description>
</item>
<item>
<title>Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-mitochondrial-disease-focused-corporate-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-mitochondrial-disease-focused-corporate-strategy</guid>
<pubDate>Thu, 06 Oct 2022 04:00:00 GMT</pubDate>
<description>Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases</description>
</item>
<item>
<title>Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-cy6463-clinical-pipeline-progress-and-second-quarter-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-announces-cy6463-clinical-pipeline-progress-and-second-quarter-2022-financial-results</guid>
<pubDate>Tue, 09 Aug 2022 04:00:00 GMT</pubDate>
<description>Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like</description>
</item>
<item>
<title>Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-positive-topline-clinical-data-for-cy6463-in-patients-with-cognitive-impairment-associated-with-schizophrenia-cias</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-positive-topline-clinical-data-for-cy6463-in-patients-with-cognitive-impairment-associated-with-schizophrenia-cias</guid>
<pubDate>Thu, 28 Jul 2022 04:00:00 GMT</pubDate>
<description>Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of</description>
</item>
<item>
<title>Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/steven-e-hyman-md-appointed-to-cyclerion-therapeutics-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/steven-e-hyman-md-appointed-to-cyclerion-therapeutics-board-of-directors</guid>
<pubDate>Tue, 26 Jul 2022 04:00:00 GMT</pubDate>
<description>Renowned neuroscience leader to further long-term clinical research strategy and external collaborations CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease</title>
<link>https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-cy6463-data-demonstrating-improved-cellular-energetics-in-preclinical-models-of-mitochondrial-disease</link>
<guid isPermaLink="true">https://6ix.com/company/cyclerion-therapeutics-inc/news/cyclerion-therapeutics-announces-cy6463-data-demonstrating-improved-cellular-energetics-in-preclinical-models-of-mitochondrial-disease</guid>
<pubDate>Fri, 17 Jun 2022 04:00:00 GMT</pubDate>
<description>CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for</description>
</item>
</channel>
</rss>